Investigational drug · Phase 2
SKB500
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Esophageal Squamous Cell Carcinoma, Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SKB500"
First trial start
2026
Jan 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKB500", any sponsor or status.
Conditions studied
As listed on its trial records.
- Esophageal Squamous Cell Carcinoma
- Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SKB500" as an intervention, largest first.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT06736327 · 180 participants (planned) · Start Dec 13, 2024 · Primary completion Jul 31, 2027
Drug: SKB500 · For: Advanced Solid Tumors
Sites: Jilin City, China
- SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaPivotal-lookingRecruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07700667 · 120 participants (planned) · Start Aug 13, 2026 · Primary completion Dec 31, 2028
Drug: SKB500; Tislelizumab and 2 more · For: Esophageal Squamous Cell Carcinoma
Sites: Changchun, China; Chengdu, China; Chongqing, China · 24 sites in all
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07296809 · 80 participants (planned) · Start Jan 30, 2026 · Primary completion Dec 31, 2028
Drug: SKB500 Powder for Injection; KL-A167 Injection and 2 more · For: Small Cell Lung Cancer
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Esophageal Squamous Cell Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.